RESEARCH TRIANGLE PARK, N.C.–Tranzyme Pharma (Nasdaq:TZYM), a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule macrocyclic compounds, today announced the successful completion of its chemistry-based drug discovery collaboration with Bristol-Myers Squibb. As a result of the joint research efforts, Tranzyme has transferred compounds to Bristol-Myers Squibb for further development across multiple drug targets. As part of this agreement, Tranzyme retains the option to further pursue select collaboration targets for internal development. (more…)

CARY, N.C.–Biologics, an integrated oncology services company, has been awarded URAC’s Health Utilization Management accreditation, which represents the company’s third URAC accreditation. Biologics was previously awarded the Core and Specialty Pharmacy accreditations from the Washington, DC-based health care organization that establishes quality standards for the health care industry. (more…)

RESEARCH TRIANGLE PARK, N.C.–Tranzyme Pharma (Nasdaq:TZYM), has announced that Richard I. Eisenstadt, Vice President, Finance and Chief Financial Officer, has resigned effective January 4, 2013, to pursue a new career opportunity. “On behalf of the entire team at Tranzyme Pharma, I would like to thank Rich for his many years of hard work and dedication at the Company during his tenure as CFO. Since joining Tranzyme in 2003, Rich has been a valuable member of our executive team. We wish him the best in his future endeavor,” said Vipin K. Garg, Ph. D., President and CEO of Tranzyme Pharma. (more…)

RESEARCH TRIANGLE PARK, N.C.–Quintiles Chief Information Officer (CIO) Richard Thomas has been named one of IDG’s Computerworld Premier 100 IT Leaders for 2013. The Premier 100 spotlights 100 leaders from both the technology and business sides of companies for their exceptional technology leadership and innovative approaches to business challenges. Now in its 14th year, this awards program shines a spotlight on technology and business leaders from a broad range of organizations who have displayed exceptional technology leadership in their organizations, fostered ideas and creative work environments, envisioned innovative approaches to business problems and effectively managed IT strategies. (more…)

RESEARCH TRIANGLE PARK, N.C.–Quintiles announced today that it has been recognized as one of the World’s Best Multinational Workplaces by the Great Place to Work® Institute, finishing 23rd on the list.  The ranking is the world’s largest annual study of workplace excellence and identifies the top-25 best multinationals in terms of workplace culture. This is Quintiles’ second appearance on the list. (more…)

(Research Triangle Park, N.C.) Quintiles ranks 6th in this year’s InformationWeek 500, a list of the top technology innovators in the United States. The annual list was revealed last night (September 11th) at an awards ceremony in Dana Point, CA. InformationWeek identifies and honors the nation’s most innovative users of information technology with its annual 500 listing, and also tracks the technology, strategies, investments and administrative practices of America’s best-known companies. The listing spotlights the power of innovation in information technology, rather than simply identifying the biggest IT spenders. (more…)

(Research Triangle Park, N.C.) To help biopharmaceutical companies dramatically improve drug development productivity and deliver greater value, Quintiles has announced the acquisition of Expression Analysis, Inc. (EA), a premier provider of genomics testing and analysis to biopharma, academic, government and non-profit customers. Terms of the transaction were not disclosed. This is the latest in a series of acquisitions and alliances designed to help Quintiles’ customers leverage the power of genomics  to better understand diseases; develop diagnostic tools; and deliver safer, more effective therapies based on the genetic makeup of the disease and the patient. (more…)

(Shanghai) In a ceremony underscoring the growing importance of China to the global biopharmaceutical industry, Quintiles executives and local dignitaries today announced agreements to establish a Quintiles regional headquarters for China in Shanghai and to significantly expand lab testing capabilities in China. Chenggang Zhu, Vice Mayor of the Shanghai Xuhui District People’s Government and executives from the Shanghai Clinical Research Centre (SCRC), Quintiles’ strategic partner in the China-based lab initiative, joined Quintiles’ executives at the ceremony. (more…)

(Washington, D.C.) I-SPY 2 (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis)  is a unique clinical trial managed as a public/private partnership by the FNIH Biomarkers Consortium. I-SPY 2 is an innovative adaptive clinical trial that is testing new drugs in high risk breast cancers in the neoadjuvant (drug treatment prior to surgery) setting, and will advance the understanding of which drugs work best with tumor types with different biomarker profiles. The Biomarkers Consortium has worked closely with the U.S. Food and Drug Administration (FDA) throughout the development of the project to promote our joint interest in improving the efficiency of clinical trials. The FDA has published a draft guidance describing a new, accelerated drug and biomarker approval paradigm for drug evaluation based on a pathological complete response (pCR) endpoint in high risk breast cancer , and an accompanying commentary (Prowell and Pazdur 2012). (more…)

(Research Triangle Park, N.C.) The constellation of stakeholders in the healthcare industry most responsible for the progress of medicine do not agree on a common lens from which to view risk for their own purposes, nor for the other stakeholders they are dependent upon. A clearer, shared understanding of risk is vital to help all stakeholders make better risk/value decisions to improve public health. (more…)

(Research Triangle Park, N.C.) Tranzyme Pharma (Nasdaq:TZYM), a late-stage biopharmaceutical company focused on discovering, developing and commercializing novel, first-in-class small molecule therapeutics for the treatment of gastrointestinal (GI) motility disorders, today announced its financial results and business update for the first quarter ended March 31, 2012. (more…)

(Durham, N.C.) Bioventus LLC, a new company providing active orthopaedic healing, launched today following the finalization of the strategic venture between the company’s owners, an Essex Woodlands led investor syndicate group and Smith & Nephew, the global medical technology business. Headquartered in Durham, N.C., Bioventus grew out of Smith & Nephew’s former Biologics and Clinical Therapies division and includes nearly 500 U.S. employees from that group, as well as innovative and successful products to help accelerate bone healing and treat osteoarthritis pain. For the time being, employees outside of the U.S. will remain with Smith & Nephew and Smith & Nephew will distribute products on behalf of Bioventus outside of the U.S. This business will be transitioned to Bioventus over time as required legal and other approvals are obtained. (more…)